Assessing ANI Pharmaceuticals (ANIP) Valuation After a Strong Yearly Share Price Rally [Yahoo! Finance]
Is ANI Pharmaceuticals Stock Price Justified After 47% 2025 Rally? [Yahoo! Finance]
How Investors May Respond To ANI Pharmaceuticals (ANIP) Creating a Retina-Focused FutureVision Advisory Council [Yahoo! Finance]
Implied Volatility Surging for ANI Pharmaceuticals Stock Options [Yahoo! Finance]
ANI Pharmaceuticals (NASDAQ:ANIP) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $100.00 price target on the stock.